Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.

Abstract

Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non-small cell lung cancer (NSCLC) positive for skipping mutations of MET exon 14 (METex14). Drug-induced interstitial lung disease (ILD) is a relatively rare, but potentially serious, side effect of TKIs administered for lung cancer treatment. Here we report a case of capmatinib-induced ILD in a patient with NSCLC harboring a METex14 skipping mutation. Capmatinib should be immediately discontinued if ILD is suspected, and treatment with corticosteroid should be considered.

• Authors: Hiroaki Kanemura, Masayuki Takeda, Shigeki Shimizu, Kazuhiko Nakagawa
• Journal: Thoracic cancer (Thorac Cancer) Vol. 12 Issue 4 Pg. 549-552 (02 2021) ISSN: 1759-7714 [Electronic] Singapore
• PMID: 33347701 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Chemical References

• Benzamides
• Imidazoles
• Triazines
• MET protein, human
• Proto-Oncogene Proteins c-met
• capmatinib

Topics

• Aged
• Benzamides (adverse effects)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology)
• Exons
• Humans
• Imidazoles (adverse effects)
• Lung Diseases, Interstitial (chemically induced, genetics)
• Lung Neoplasms (drug therapy, genetics, pathology)
• Male
• Mutation
• Proto-Oncogene Proteins c-met (genetics)
• Triazines (adverse effects)